Ipatasertib-NH2 is primarily used in the development of targeted cancer therapies, particularly in the treatment of solid tumors. It functions as a potent inhibitor of the AKT pathway, which is often dysregulated in various cancers, leading to uncontrolled cell growth and survival. By blocking this pathway, it helps to induce apoptosis in cancer cells and inhibit tumor progression. This compound is particularly significant in research focused on breast, prostate, and ovarian cancers, where AKT signaling plays a critical role. Additionally, it is utilized in preclinical studies to explore combination therapies, enhancing the efficacy of existing treatments like chemotherapy and immunotherapy. Its application extends to the development of biomarkers for patient stratification, ensuring personalized and effective treatment strategies.